Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer

被引：77

作者：

Bahrami, Afsane ^{[1
]}

Hassanian, Seyed Mahdi ^{[2
,3
]}

ShahidSales, Soodabeh ^{[4
]}

Farjami, Zahra ^{[1
]}

Hasanzadeh, Malihe ^{[5
]}

Anvari, Kazem ^{[4
]}

Aledavood, Amir ^{[4
]}

Maftouh, Mina ^{[2
]}

Ferns, Gordon A. ^{[6
]}

Khazaei, Majid ^{[7
]}

Avan, Amir ^{[2
,4
]}

机构：

[1] Mashhad Univ Med Sci, Dept Modern Sci & Technol, Fac Med, Mashhad, Iran

[2] Mashhad Univ Med Sci, Metab Syndrome Res Ctr, Mashhad, Iran

[3] Mashhad Univ Med Sci, Sch Med, Dept Med Biochem, Mashhad, Iran

[4] Mashhad Univ Med Sci, Canc Res Ctr, Fac Med, Mashhad, Iran

[5] Mashhad Univ Med Sci, Dept Gynecol Oncol, Woman Hlth Res Ctr, Mashhad, Iran

[6] Brighton & Sussex Med Sch, Div Med Educ, Brighton, Sussex, England

[7] Mashhad Univ Med Sci, Dept Physiol, Fac Med, Mashhad, Iran

来源：

JOURNAL OF CELLULAR PHYSIOLOGY | 2018年 / 233卷 / 03期

关键词：

cetuximab; colorectal cancer; KRAS; novel anticancer agent; KRAS-MUTANT LUNG; WILD-TYPE KRAS; COMBINATION THERAPY; 1ST-LINE TREATMENT; MEK INHIBITION; CETUXIMAB; CHEMOTHERAPY; IRINOTECAN; MUTATIONS; RESISTANCE;

D O I：

10.1002/jcp.25890

中图分类号：

Q2 [细胞生物学];

学科分类号：

071013 [干细胞生物学];

摘要：

The V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) is frequently dysregulated in colorectal cancer (CRC). It is involved in the modulation of several downstream effectors, that include: Raf/Mek/Erk, PI3K/Akt, RalGDS/p38MAPK, and Rac/Rho, and thereby influences tumorigenesis, the invasive behaviors of tumor cell, and resistance to therapy. There is growing evidence exploring the use of drugs that target these pathways in the treatment of CRC. Cetuximab has been approved for CRC patients without a KRAS mutation, or for EGFR-expressing metastatic CRC, although some of the patients have a mutation of KRAS and NRAS. This review summarizes the recent knowledge about the therapeutic potential of targeting RAS with particular emphasis on recent preclinical and clinical studies in treatment of CRC.

引用

页码：2058 / 2066

页数：9

共 59 条

[1]

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[2]

[Anonymous], J CLIN ONCOL

[3]

[Anonymous], 2014, J CLIN ONCOL, DOI DOI 10.1200/JC0.2014.32.15_SUPPL.9051

[4]

Development of farnesyl transferase inhibitors: A review [J].

Appels, NMGM ;

Beijnen, JH ;

Schellens, JHM .

ONCOLOGIST, 2005, 10 (08) :565-578

[5]

A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling [J].

Athuluri-Divakar, Sai Krishna ;

Vasquez-Del Carpio, Rodrigo ;

Dutta, Kaushik ;

Baker, Stacey J. ;

Cosenza, Stephen C. ;

Basu, Indranil ;

Gupta, Yogesh K. ;

Reddy, M. V. Ramana ;

Ueno, Lynn ;

Hart, Jonathan R. ;

Vogt, Peter K. ;

Mulholland, David ;

Guha, Chandan ;

Aggarwal, Aneel K. ;

Reddy, E. Premkumar .

CELL, 2016, 165 (03) :643-655

[6]

Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC) [J].

Atreya, Chloe Evelyn ;

Van Cutsem, Eric ;

Bendell, Johanna C. ;

Andre, Thierry ;

Schellens, Jan H. M. ;

Gordon, Michael S. ;

McRee, Autumn Jackson ;

O'Dwyer, Peter J. ;

Muro, Kei ;

Tabernero, Josep ;

van Geel, Robin ;

Sidhu, Roger ;

Greger, James G. ;

Rangwala, Fatima A. ;

Motwani, Monica ;

Wu, Yuehui ;

Orford, Keith W. ;

Corcoran, Ryan Bruce .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

[7]

Antibody-Mediated Delivery of Anti-KRAS-siRNA In Vivo Overcomes Therapy Resistance in Colon Cancer [J].

Baeumer, Sebastian ;

Baeumer, Nicole ;

Appel, Neele ;

Terheyden, Lisa ;

Fremerey, Julia ;

Schelhaas, Sonja ;

Wardelmann, Eva ;

Buchholz, Frank ;

Berdel, Wolfgang E. ;

Mueller-Tidow, Carsten .

CLINICAL CANCER RESEARCH, 2015, 21 (06) :1383-1394

[8]

C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives [J].

Bahrami, Afsane ;

Shahidsales, Soodabeh ;

Khazaei, Majid ;

Ghayour-Mobarhan, Majid ;

Maftouh, Mina ;

Hassanian, Seyed Mahdi ;

Avan, Amir .

JOURNAL OF CELLULAR PHYSIOLOGY, 2017, 232 (10) :2657-2673

[9]

Therapeutic Potential of Targeting Wnt/-Catenin Pathway in Treatment of Colorectal Cancer: Rational and Progress [J].

Bahrami, Afsane ;

Amerizadeh, Forouzan ;

ShahidSales, Soodabeh ;

Khazaei, Majid ;

Ghayour-Mobarhan, Majid ;

Sadeghnia, Hamid Reza ;

Maftouh, Mina ;

Hassanian, Seyed Mahdi ;

Avan, Amir .

JOURNAL OF CELLULAR BIOCHEMISTRY, 2017, 118 (08) :1979-1983

[10]

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 [J].

Barbie, David A. ;

Tamayo, Pablo ;

Boehm, Jesse S. ;

Kim, So Young ;

Moody, Susan E. ;

Dunn, Ian F. ;

Schinzel, Anna C. ;

Sandy, Peter ;

Meylan, Etienne ;

Scholl, Claudia ;

Froehling, Stefan ;

Chan, Edmond M. ;

Sos, Martin L. ;

Michel, Kathrin ;

Mermel, Craig ;

Silver, Serena J. ;

Weir, Barbara A. ;

Reiling, Jan H. ;

Sheng, Qing ;

Gupta, Piyush B. ;

Wadlow, Raymond C. ;

Le, Hanh ;

Hoersch, Sebastian ;

Wittner, Ben S. ;

Ramaswamy, Sridhar ;

Livingston, David M. ;

Sabatini, David M. ;

Meyerson, Matthew ;

Thomas, Roman K. ;

Lander, Eric S. ;

Mesirov, Jill P. ;

Root, David E. ;

Gilliland, D. Gary ;

Jacks, Tyler ;

Hahn, William C. .

NATURE, 2009, 462 (7269) :108-U122

← 1 2 3 4 5 6 →